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HOUSTON LAW REVIEW
FOREWORD
BIOETHICS POLICY: LOOKING BEYOND
THE POWER OF SOVEREIGN GOVERNMENTS
Robert Schwartz*
Lawyers are trained to think in terms of power exercised by
a sovereign-an institution authorized to enforce a procedurally
appropriate decision with coercive force.' Generally, lawyers
have a broad notion of what constitutes a sovereign. In the
United States, for example, this notion includes the federal gov-
ernment, state governments, most tribal units, traditional terri-
torial governments and their agencies-e.g., school boards, local
public park districts, water run-off management districts, and
flea abatement boards-and a host of other institutions. As a re-
sult, it is difficult for lawyers to recognize that policy also may
emanate from other institutions that possess only persuasive
authority, not coercive power.
Of course, it makes sense for lawyers to focus on the imple-
mentation of law through sovereign power. The criminal law has
. Dr. Arthur Grayson Visiting Professor of Law and Medicine, Southern Illi-
nois University; Professor of Law and Pediatrics, University of New Mexico; A.B.,
Stanford University, 1970; J.D., Harvard Law School, 1975.
1. Although the word "sovereign" has been attributed a number of meanings,
it includes the characteristics of independence and authority, unbridled except by
internal sources. See BLACICS LAW DICTIONARY 1395 (6th ed. 1990) (defining sover-
eign as "[a] ... state in which independent and supreme authority is vested.....).
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virtually no meaning outside of such power, 2 and everything
from health policy 3 to arts policy 4 is, at least in part, made
through the exercise of sovereign power. It may turn out, how-
ever, that in bioethics,5 which is permeated with values that vary
from person to person, family to family, and group to group, 6
authorities that seek to persuade, cajole, and shame can do more
to create effective policy than those that exercise coercive power.
It is not surprising that lawyers have attempted to analyze
bioethics policy by focusing on the exercise of governmental
authority. Within the law, issues surrounding research on hu-
man subjects have been perceived primarily as regulatory issues
for national governments. 7 Similarly, legislatures from the Neth-
erlands8 to the Northern Territory9 have expended a great deal
2. Though we sometimes talk about edification and other functions of the
criminal law, it is difficult to find a curriculum that does not focus on the coercive
power of that law. For while the law may intend to "awaken... voluntary inclina-
tion toward a certain cause of action," it does so primarily through its ultimately co-
ercive effect. See YVES R. SIMON, PHILOSOPHY OF DEMOCRATIC GOVERNMENT 109-10
(1951) (restating Thomas Aquinas's theory that through coercion, governments cre-
ate "good habits" in wrongdoers).
3. The American health care system is regulated by literally thousands of
federal and state statutes and regulations, and nearly half of it is financed by gov-
ernment-appropriated dollars. See BARRY R. FURROW ET AL., HEALTH LAW chs. 11-
14 (1995) (discussing government regulation of both public and private health care
financing mechanisms and stating that the government paid 42% of all health care
costs in 1990).
4. In the United States, arts policy is to a large degree dictated by the sub-
stantive rules for grant funding by the National Endowment for the Arts (NEA). See
Bella Lewitzky Dance Found. v. Frohnmayer, 754 F. Supp. 774, 783 (C.D. Cal. 1991)
(noting that NEA funding maintains substantial influence in the United States art
world). For an account of how the United States Congress established arts policy
over the past year. see Cassandra Burrell, Budget Cuts Blamed for Hurting Art.
ROCKY MOUNT. NEWS. May 9, 1996, at A44 (reporting that congressional Republi-
cans "succeeded in shaking up the endowment and cutting its $167.4 million budget
for 1995").
5. The term "bioethics" includes the principle-based discussion of public policy
issues arising out of the biological development of human beings and their relation-
ships. See 1 ENCYCLOPEDIA OF BIOETHICS xix (Warren T. Reich ed., 1978).
6. See id.; cf. Kevin Win. Wildes, Particularism in Bioethics: Balancing Secu-
lar and Religious Concerns, 53 MD. L. REV. 1220, 1220 (1994) (stating that contro-
versies arise in the field of bioethics "because there are different views concerning
... how medicine should be practiced").
7. For the regulations in force in the United States, see 21 C.F.R. §§ 56.101-
.124 (1996), the regulations promulgated by the Department of Health and Human
Resources, and parallel regulations issued by other agencies. For a general account
of government regulation of medical research, see ROBERT J. LEVINE, ETHICS AND
REGULATION OF CLINICAL RESEARCH (2d ed. 1986).
8. The society-wide debate over physician-assisted death has been reflected in
the Dutch legislature and, more recently, the legislative definition of the appropri-
ate methods of physician-assisted death. For a discussion of this debate from an in-
ternational law perspective rather than a bioethics perspective, see Julia Belian,
Comment, Deference to Doctors in Dutch Euthanasia Law, 10 EMORY INT'L L.J. 255
(1996).
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of energy over the past few years debating the merits and appro-
priate limitations of a formal legal recognition of physician-
assisted death. In parts of Africa, national governments and
their local subdivisions have confronted the practice of female
genital surgery10 and caused some countries to abolish the prac-
tice.1 Virtually every government in the world has been con-
fronted with the need for sovereign intervention to affect distri-
bution of health care resources or the regulation of the market
that provides for such distribution.1 2 These are serious issues
upon which sovereign governments attempt to bring their
knowledge of science, their national values, their social re-
sources, and their good sense to bear in establishing enforceable
law.
In a sense, we are watching the laboratory of the nations at
work in developing bioethics policy. Many governments are
watching the Dutch experience with physician-assisted death, as
they also keep an eye on the experiences in Oregon, 13
9. In 1995, the Northern Territory became the first Australian legislature to
legalize physician-assisted death. See Rights of the Terminally Ill Act. No. 12 (1995)
(NT). For an account of the legislative process that led to this development and a
description of the international interest in this law, see Philip Shenon, Australian
Doctors Get Right to Assist Suicide, N.Y. TIMES. July 28, 1995, at AS. An interesting
compilation of different national responses to this issue is found in Legal Systems
Handle Euthanasia Differently Around the Globe. LA TBIES. Mar. 14. 1993. at A9.
10. For one recent account of the global debate over female genital surgery, see
Sandra D. Lane & Robert A. Rubinstein, Judging the Other: Responding to Tradi-
tional Female Genital Surgeries, HASTINGS CENTER REP.. May-June 1996. at 31. For
a discussion of the medical, legal, and ethical considerations involved, see Nahid
Toubia, Female Circumcision as a Public Health Issue. 331 NEW ENG. J. MED. 712
(1994).
11. See Lane & Rubinstein, supra note 10, at 36-37. Parliaments in Sweden.
the United Kingdom, and the Netherlands have passed legislation prohibiting fe-
male circumcision. See id. at 35. See generally Elise A. Sochart, Agenda Setting, the
Role of Groups and the Legislative Process: The Prohibition of Female Circumcision
in Britain, 41 PARIMEENTARYAFF. 508 (1988).
12. See Robert H. Blank, Rationing Medicine: A Comparative Analysis, 21 W.
ST. U. L. REV. 11, 11 (1993) ("No developed nation will be spared from difficult deci-
sions concerning the allocation of health care resources.").
13. The Oregon Death With Dignity Act was codified in 1994. See OR. REV.
STAT. ANN. §§ 127.800-.895 (Supp. 1996). The Act would permit physician-assisted
suicide, but not euthanasia, under limited circumstances. See id. (requiring, among
other things, confirmation of a diagnosis that a requesting patient suffers from a
terminal disease). However, an injunction against the application of the Act was is-
sued in Lee v. Oregon, 869 F. Supp. 1491, 1503 (D. Or. 1994).
Subsequently, in Lee v. Oregon, 891 F. Supp. 1429 (D. Or. 1995), the Act
was held unconstitutional because it violated the Equal Protection Clause of the
Fourteenth Amendment. See id. at 1438. More recently, the United States Supreme
Court heard arguments challenging the constitutionality of state prohibitions of
physician-assisted suicide. See Steve Lash, Justices Wrestle with Whether Constitu-
tion Protects Doctor Assisted Suicide, WEST LEG. NEWS, Jan. 9, 1997, available in
1997 WL 14249 (reporting on challenges to Washington and New York statutes that
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the Northern Territory, 14 and a host of other legislatures, in-
cluding many of the United States, that are contemplating bills
that would permit physician-assisted death under certain cir-
cumstances. 15 Similarly, African nations are watching develop-
ments in other nations that have decided to use their sovereign
power to eliminate the practice of female genital surgery. 16
Countries are watching others experiment with different legal
devices designed to make pharmaceuticals more available to
members of their society. 17 Much of the world is also watching
the remarkable variety of health care financing mechanisms that
have been established over the last half century.18 For example,
the American focus on making the market work within health
care through the creation of managed competition 9 has provided
a substantial influence on health care systems from the United
Kingdom, where reform has created an "'internal market"'
within the national health system, 20 to Cambodia, where market
mechanisms are being considered as a way to provide incentives
for the creation of a national health care system from scratch. 21
prohibit physician-assisted suicide and noting that the Supreme Court will an-
nounce a decision by summer 1997).
14. Refer to note 9 supra.
15. For a discussion of the physician-assisted death initiatives being consid-
ered by the legislatures of Michigan, Nevada, New Hampshire, Rhode Island, and
Virginia, see Kevin M. Stansbury, Note, 31 LAND & WATER L. REV. 623, 637 n.132
(1996).
16. Refer to notes 10-11 supra and accompanying text.
17. In fact, some countries have joined together formally to address the
"scientific, cultural, and technical problems that obstruct drug development and im-
portation" in an attempt to increase the availability of pharmaceuticals to their re-
spective citizens. See Joseph G. Contrera, Comment, The Food and Drug Admini-
stration and the International Conference on Harmonization: How Harmonious Will
International Pharmaceutical Regulations Become?, 8 ADMIN. L.J. AM. U. 927, 929
(1995) (reporting on the Second International Conference on Harmonization and the
participation therein by the European Union, the United States, and Japan).
18. For a thorough account of the various financing systems employed in Can-
ada, Europe, and the United States, see Uwe E. Reinhardt, Reforming the Health
Care System: The Universal Dilemma, 19 AM. J.L. & MED. 21 (1993).
19. See Robert Pear, Clintons Should Address Health Care One Issue at a
Time, Experts Suggest, N.Y. TIMES, Oct. 10, 1994, at B7 (reporting that "the main-
stream coalition," a bipartisan group of senators that included Bob Dole, proposed
health care legislation based on managed competition). For an account of the impact
of managed competition on the debate over health care reform in the United States,
see Paul M. Ellwood et al., The Jackson Hole Initiatives for a Twenty-First Century
American Health Care System, 1 HEALTH EcoN. 149 (1992).
20. See Frances H. Miller, Denial of Health Care and Informed Consent in
English and American Law, 18 AM. J.L. & MED. 37, 52-54 (1992) (discussing the ef-
fects on Britain's National Health Service). For an interesting political account of
this development, see Steve Lohr, Free-Market Health System: New Thatcher Goal
for Britain, N.Y. TIMES, Feb. 1, 1989, at Al.
21. See generally WORLD HEALTH ORGANIZATION, STRENGTHENING HEALTH
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As the thoughtful Articles in this Symposium prove, how-
ever, legal scholars are beginning to recognize that enforcement
by sovereign authority is not the best way to address many of
these issues. There are devices-even formal legal devices-that
will allow us to develop better bioethics policy than we could
achieve through the enforcement of the law. Consider the situa-
tion in Michigan, where three separate juries, each hearing a
separate criminal case against Dr. Jack Kevorkian, showed us
that sometimes the majority does not want to enforce the law-
even though that same majority is reluctant to change that effec-
tively unenforceable law through the use of its democratic insti-
tutions.22 While juries were acquitting Dr. Kevorkian, the Michi-
gan legislature decided that his conduct should remain
criminal. 23 The conversation about physician-assisted death that
resulted from the Kevorkian cases may lead us to a social con-
sensus on that issue of bioethics policy; new enforceable laws-
whether they attempt to prohibit physician-assisted death, as in
Michigan, or permit it under some circumstances, as in Oregon-
are far less likely to resolve the underlying social issue. Even the
distribution of health care resources, including pharmaceuticals,
might improve if it is removed from the clutches of the sovereign
and delegated to other institutions, such as the market.
The goal of health and bioethics policy generally is to maxi-
mize the quality of health of those touched by the policy. But
health is not the only value that we prize, and it is not the only
value that is touched by health policy. To the extent that any
such policy also touches cultural identity, national sovereignty,
local integrity and decision making, international trade and in-
ternational intercourse of all kinds, or the international image of
governments, the policy must be a compromise that recognizes
all of these values. In fact, many of these values-the cultural
identity of minorities, for example-are not the prevailing values
in a democratic nation. Values of individual families are more
likely to be expressed in a policy if those families are involved in
making the policy, and policies that affect particular ethnic
SERVICES (1994).
22. See Jack Lessenberry, Keuorkian Indicted on Charges of Helping in Three
Suicides, N.Y. TIMES, Nov. 1, 1996, at A32 (reporting that Dr. Kevorkian was ac-
quitted three times on assisted suicide charges).
23. The Michigan legislature created the crime of assistance to suicide in 1992,
but it carried with it a sunset provision; the sunset provision has since expired. See
MICH. COMP. LAWS ANN. § 752.1027 (Supp. 1996). For a brief description of Dr. Kev-
orkian's travails in the Michigan courts, and for a discussion of how the Michigan
legislature and courts addressed the issue, see BARRY R. FURROW El AL., HEALTH
LAW: CASES, MATERIALS AND PROBLEMS 283-85 (Supp. 1996).
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groups are more likely to be satisfactory if those ethnic groups
are sources of the policy. In a world where political boundaries
are arbitrary, policies articulated by sovereign nations may be
enforceable but they are not, per se, justifiable. We may be better
off with more rationally created and justifiable policies, even if
they are not so cleanly enforceable. Further, by placing the re-
sponsibility for health and bioethics policy decision making in
those that have the power to persuade and convince, but not to
enforce-by placing decision making in bodies that are not sov-
ereign-we may avoid some of the abuse that comes with giving
power over such fundamental issues to already powerful gov-
ernments. Additionally, we may create a diversity of decision
making that will allow for better, more universal, and more con-
sistent policies around the globe.
All of the Articles in this Symposium recognize that the
health of our community may be advanced more substantially if
policy making is in the hands, as least in part, of unofficial, non-
sovereign bodies with no real power of enforcement. First, Pro-
fessor Lars Noah explains the potential effects of the North
American Free Trade Agreement (NAFTA) on the trade in
pharmaceuticals. 24 Professor Noah's thorough account provides
us with a story of how bioethics policy will be made, effectively,
outside of sovereign governments. As Professor Noah explains,
NAFTA, which provides stronger intellectual property rights and
enforcement mechanisms, 25 lowers tariffs,26 formally permits
open bidding across North America, 27 and governs cross-border
purchases (which thus could affect the gray market),28 is unlikely
to substantially alter the current trade in pharmaceuticals
throughout this continent. 29 However, Professor Noah's ap-
proach, which is based upon the presumption that such issues
should be resolved in the market, suggests that the distribution
of pharmaceuticals throughout North America (and, presumably,
the world) may be advanced if we allow the international market
in those drugs to develop fully, and leave the governments to the
comparatively narrower task of protecting the intellectual prop-
erty rights of those developing the pharmaceuticals.
Allyn L. Taylor's contribution to this Symposium provides us
with an exceptionally clear description of how the International
24. See Lars Noah, NAFTA's Impact on the Trade in Pharmaceuticals, 33
Hous. L. REV. 1293 (1997).
25. See id. at 1297-1302.
26. See id. at 1309.
27. See id. at 1311-15.
28. See id.
29. See id. at 1314-15.
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Health Regulations (IR, or Regulations) could help contain the
spread of infectious diseases. 30 The Regulations, which origi-
nated in the World Health Organizations International Sanitary
Regulations in 1951 and were last revised in 1981, have not
proven adequate to deal with infectious disease transmission
over the past few years.3' Consequently, Ms. Taylor suggests
that the IHR be rewritten to create an independent agency of the
World Health Organization (or the World Health Assembly) that
will not partake of any sovereignty of any of the members of the
World Health Organization, and will not have any of the author-
ity of the World Health Organization itself.32 Rather, it will have
the power to provide assistance when it is requested, to seek in-
formation, and to congratulate or shame those who do (or fail to)
live up to the regulations. 33 The power of sovereign nations is not
sufficient to resolve this problem in a world fractured by arbi-
trary international boundaries that are unrespected by patho-
gens, but that does not mean our effort to control disease must
fail. It simply means that we must look elsewhere to persuade
sovereign nations into compliance.
In their contribution to this Symposium, Ms. Le Bris, Pro-
fessor Knoppers, and Ms. Luther remind us that there are sev-
eral sources of bioethics decision making that do not partake of
sovereign power. 34 The participation of these diverse nonsover-
eign decision makers in the global bioethics debate, the authors
argue, will facilitate policies that are more "adaptive and evolu-
tionary" than those that typically evolve from traditional linear
consensus building.35 The authors do not seek to supplant the
traditional positive principles of bioethics, however. They simply
believe that combinations of these nonsovereign decision makers
are more flexible and more able than governments to accommo-
date the nonlinear policy development that health and bioethics
policy necessitates. 3 6
While the first three Articles deal, directly or indirectly,
with international (or, at least, multinational) law, Professor
Henry Greely's Article does not.37 His suggestion is that some
30. See Allyn L. Taylor, Controlling the Global Spread of Infectious Diseases:
Toward a Reinforced Role for the International Health Regulations. 33 HOUS. L.
REV. 1327 (1997).
31. See id. at 1341-46.
32. See id. at 1346-52.
33. See id. at 1352-60.
34. See Sonia Le Bris, Bartha Maria Knoppers. Lori Luther, International Bio-
ethics, Human Genetics, and Normativity, 33 HOUS. L. REV. 1363, 1364-74 (1997).
35. See id. at 1393-95.
36. See id. at 1392-95.
37. See Henry T. Greely, The Control of Genetic Research: Involving the
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bioethics policy-at the least, policy regarding the maintenance
of genetic information-ought to be set by "groups between" the
individual,38 who is generally recognized by law as the one with
authority to grant consent to research upon his body (and, pre-
sumably, his genome),39 and the sovereign state, which makes
and enforces that law and has the independent authority to
regulate bioethics and, more particularly, genetics research pol-
icy.40 Professor Greely's concern arises out of his participation in
the Human Genome Diversity Project (HGDP), a particularly ex-
citing undertaking that plans to obtain, catalog, and maintain
genome samples from hundreds of different sources around the
world.41
The proposed Model Ethical Protocol for Collecting DNA
Samples from the North American Regional Committee Human
Genome Diversity Project, which is also included in this Sympo-
sium, 42 provides a description of how some of these "groups be-
tween" can be defined, and what might constitute "a culturally
appropriate" authority to grant consent on the groups' behalf.43
But how are the decisions of these groups to be enforced? They
do not have the legal status of individuals, nor do they have the
legal authority of sovereign governments, for the most part. As
Professor Greely points out, they will be enforced by the private
institutions that choose to be bound by them.44 For example, the
HGDP proposes that it not collect or maintain any DNA samples
that do not meet the requirements of the proposed Model Proto-
col. 45 Professor Greely's proposed method of enforcement is re-
markably similar to Ms. Taylor's method of enforcement of the
IHR. When an Institutional Review Board or a funding agency
refuses to make a reasonable effort to define the "group between"
and discover "a culturally appropriate" authority to consent on
behalf of that group, others, including the HGDP, will make sure
the community knows of this transgression. 46 Shame and public
"Groups Between," 33 HOUS. L. REV. 1397 (1997).
38. See id. at 1408-13.
39. See id. at 1405-08.
40. See id. at 1399-1405.
41. See id. at 1414.
42. See Proposed Model Ethical Protocol for Collecting DNA Samples, 33
HOUS. L. REV. 1431 (1997) [hereinafter Model Protocol].
43. See id. at 1443-47.
44. See Greely, supra note 37, at 1414-20.
45. See Model Protocol, supra note 42, at 1436.
46. See Greely, supra note 37, at 1425; Model Protocol, supra note 42, at 1437-
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approbation are the weapons available to those that wish to en-
force the guidelines; there may be no better way of enforcing the
principles of bioethics.
Together, the four Articles in this Symposium demonstrate
the strength of bioethics institutions that do not grow out of sov-
ereign governments. Perhaps we have entered an era where the
value of engaging nonsovereign institutions in policy making is
seen as valuable across disciplinary lines. These authors, for ex-
ample, apply their theories to the market for pharmaceuticals,
the International Health Regulations, and the collection of ge-
netic information. The challenge for the bioethics community is
to take the principles developed here and to apply them to other
pressing issues, including physician-assisted death, female geni-
tal surgery, the request for futile medical care, designing proper
regulation for a managed care system, and, perhaps, providing a
just and equitable distribution of health care resources in this
country and around the world.
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